Radisys Celebrates Six Engage Digital Platform Winners of TADHack 2022 Hackathon
8.11.2022 22:30:00 EET | Business Wire | Press release
Radisys® Corporation, a global leader of open telecom solutions, is pleased to highlight the winners of the Engage Digital Platform real-world solutions in the 2022 TADHack Global, a hackathon focused on programmable communication solutions. Radisys provided participants in the Telecom Application Development (TAD) with access to its award-winning, no-code or low-code Engage Digital Platform to develop software projects or “hacks” that address customer challenges or use cases. Radisys’ Engage Digital Platform provides developers with a complete toolkit to create a full range of communication services, from voice and video calling, speech analytics and robust conversational AI-enabled digital engagement solutions.
The TADHack Global hackathon took place October 15-16, 2022, with participants competing across several cities and online. Radisys selected six winners, including a tie for third place and two specialized categories, for the best hacks from among the 23 submissions using Radisys’ Engage Digital Platform.
“I want to congratulate all of the 2022 TADHack Global event winners, especially those teams that leveraged Radisys’ Engage Digital Platform to develop such innovative solutions,” said Al Balasco, Head of Media, Core and Applications Business, Radisys. “The development of these amazing real-world solutions over a weekend was impressive and underscores the speed at which new ideas and applications can be developed and implemented. Hackathons like TADHack are a great way to showcase how MSPs and system integrators can benefit from an innovative developer ecosystem that is equipped with APIs and SDKs to create powerful advanced media applications they can integrate and offer as new services.”
Engage Digital Platform TADHack Global Winners
- First Place – Field Workforce Helper provides information from the inventory to support field workforce tasks, and routes Guard calls to the guard operator using an agenda in a Google spreadsheet, finally logging the call information in the spreadsheet. Team Member: Nacho Garmilla.
- Second Place – Secret Babble makes multilingual conversations more accessible by providing translations over the phone which can be read out loud by the system or sent discreetly as a text message, providing a transcription of the exchange. Team: Similarly Geeky; Team Members: Steve Goodwin & Lily Madar.
- Third Place – Blink is an application for crowded places designed to reduce the crowd and give people easy access to information about that particular place. It is used in places like hospitals, banks, shops, and airports, etc. Team: Sibane IT Solutions; Team Member: Linda Mosemaka.
- Third Place – Live Connect lets users connect to experts around the world for things such as learning a new language or finding a math or music tutor, to getting golf swing help and anything in between. Live Connect helps users find a suitable expert, book an appointment and connect via computer or phone using Radisys video APIs to bring the expert into customers’ homes. Team: Live Connect; Team Member: John Cakesy.
- Best Industry 4.0 Hack – FiremeX is a fire detection and alerting system that integrates computer vision, alert notifications and real-time audio calling when an event is detected. Team: RegeX; Team members: Nandula Perera, Raveen Fernando, Suvin Kodituwakku, Dilan Perera, Thenuka Ovin Weerasinghe.
- Disruptive Digital Engagement Hack – LifeVerse is a real-time health engagement platform that enables different types of clinics to be created and managed in the metaverse for both appointments and real-time consultations with patients. Team: LifeVerse; Team Members: Fahad Mahmood, Sarmad Faheem, Faheem Azhar.
To view videos of the six Engage Digital Platform winners and see all of the TADHack 2022 hacks visit https://www.engagedigital.ai/tadhack22.
About Radisys
Radisys, a global leader in open telecom solutions, enables service providers to drive disruption with new open architecture business models. Radisys’ innovative disaggregated and virtualized enabling technology solutions leverage open reference architectures and standards, combined with open software and hardware to power business transformation for the telecom industry, while its world-class services organization delivers systems integration expertise necessary to solve communications and content providers’ complex deployment challenges. For more information, visit www.radisys.com.
Radisys Engage Digital Platform was named both a 2022 Unified Communications Product of the Year Award winner and a Communications Product of the Year Award winner by TMC, a global, integrated media company covering multiple markets within the communications and technology industries, and won the Innovation in Digital Experience award in the 2022 Pipeline Innovation Awards, which recognizes the leading innovators transforming the industry with the most significant technological advancements. Engage Digital Platform was also named a “Highly Commended Best Comms Software” by the 2022 Comms Council UK Awards, a celebration of innovation in the telecom industry, and was selected as a finalist in the Best CPaaS Platform Award category by UC Today, a leading online publication for unified communications (UC) and collaboration technology. For more information, visit www.engagedigital.ai.
Radisys® is a registered trademark of Radisys. All other trademarks are the property of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221108006102/en/
Contact information
Nereus for Radisys
Matt Baxter, +1-503-619-0505
radisys@nereus-worldwide.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom